Psychosis and Mania Emerging After Abrupt Tirzepatide Discontinuation: Two Clinical Reports
Psychotic Episodes Following Sudden Cessation of Weight Loss Injections: Two Case Studies
According to НВ — Техно: Although definitive conclusions cannot yet be drawn, medical professionals have documented two instances of psychosis and mania occurring in men shortly after they abruptly stopped receiving tirzepatide injections-a GLP-1-based medication used for weight reduction. These cases were recently published in the journal Primary Care Companion for CNS Disorders.
In the first case, a 61-year-old man developed Cotard's syndrome, while the second, a 52-year-old man, experienced a manic episode. Researchers suggest a potential link between the sudden withdrawal of GLP-1 drugs and the onset of psychiatric symptoms, though direct evidence remains limited.
Clinical Presentation and Management
The 61-year-old patient was admitted to the hospital in October 2025 exhibiting confusion, depression, paranoia, as well as auditory and visual hallucinations. He had discontinued tirzepatide two months prior due to nausea. The second patient was hospitalized the same month, presenting with symptoms characteristic of mania, including:
- rapid and pressured speech,
- grandiose delusions,
- impulsivity and irritability.
This younger patient had stopped tirzepatide one month earlier after losing approximately 45 kilograms over six months. Notably, he also increased his cannabis use and was found to have a vitamin B12 deficiency before hospitalization.
Both men were transferred to psychiatric care facilities for continued treatment. Data from a European database report 481 cases of mental health disturbances linked to the use of semaglutide, liraglutide, and tirzepatide. These psychiatric events account for just over 1% of all adverse reaction reports related to these medications.
It is important to recognize that GLP-1 receptors are present not only throughout the body but also within the brain, with GLP-1 drugs capable of crossing the blood-brain barrier.
Both patients had prior histories of mental health conditions-one with depressive syndrome and the other with an anxiety disorder. The researchers emphasize the need for healthcare providers to carefully consider the possible psychiatric effects when prescribing, adjusting, or discontinuing GLP-1 therapies.
These cases highlight the critical need for caution when using weight loss medications that influence metabolic processes and brain function.
With the growing popularity of GLP-1-based treatments for obesity, clinicians should remain vigilant about the risk of psychiatric complications arising either during therapy or following abrupt cessation. Further investigation into these neuropsychiatric outcomes is essential to safeguard patients pursuing significant weight loss through pharmacological means.
As research continues to unveil the complexities of GLP-1 medications, it's worth noting that other drugs like retatrutide have also been associated with unexpected side effects. Recent findings indicate that unregulated use of retatrutide can lead to increased appetite, sleep disturbances, and heart palpitations. Exploring these new adverse reactions may provide further insight into the potential risks linked to weight loss treatments.
Read also

